Vancouver, United States
Absci is a forward-thinking company blending AI innovation with biopharmaceutical advancements. Founded in 2011 and headquartered in the United States, the company targets the intersection of AI and biopharma.
With the slogan “Unlocking differentiated biology with generative AI,” Absci emphasizes its unique approach to drug discovery. It employs a data-first AI strategy through its Integrated Drug Creation platform, crafted to design therapeutics and optimize drug leads for challenging biological targets.
Recently, the company secured a $64.00M post-IPO equity investment on 01 September 2025, underscoring investor confidence in its cutting-edge combination of biotechnology and artificial intelligence. This funding positions Absci to further enhance its pioneering drug creation technologies.
For investors, Absci represents a robust opportunity in the rapidly evolving fields of AI and biotechnology, focusing on creating differentiated therapeutics with high market potential.
